Real-life comparison of efficacy and safety profiles of two prolonged-release tacrolimus formulations in de novo kidney transplant recipients: 24 months of follow-up.
Paulina CzarneckaKinga CzarneckaTeresa BaczkowskaBeata LagiewskaMagdalena DurlikPublished in: PloS one (2023)
Both prolonged-release formulations of tacrolimus are safe and effective in immunosuppressive therapy in kidney transplant recipients.